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In this study, the human cerebrospinal fluid (CSF) proteome
was mapped using three different strategies prior to Or-
bitrap LC-MS/MS analysis: SDS-PAGE and mixed mode re-
versed phase-anion exchange for mapping the global CSF
proteome, and hydrazide-based glycopeptide capture for
mapping glycopeptides. A maximal protein set of 3081 pro-
teins (28,811 peptide sequences) was identified, of which
520 were identified as glycoproteins from the glycopeptide
enrichment strategy, including 1121 glycopeptides and their
glycosylation sites. To our knowledge, this is the largest
number of identified proteins and glycopeptides reported
for CSF, including 417 glycosylation sites not previously
reported. From parallel plasma samples, we identified 1050
proteins (9739 peptide sequences). An overlap of 877 pro-
teins was found between the two body fluids, whereas 2204
proteins were identified only in CSF and 173 only in plasma.
All mapping results are freely available via the new CSF
Proteome Resource (http://probe.uib.no/csf-pr), which can
be used to navigate the CSF proteome and help guide the
selection of signature peptides in targeted quantitative
proteomics. Molecular & Cellular Proteomics 13: 10.1074/
mcp.M114.038554, 3152–3163, 2014.
Cerebrospinal fluid (CSF)1 surrounds and supports the cen-
tral nervous system (CNS), including the ventricles and sub-
arachnoid space (1). About 80% of the total protein amount in
CSF derives from size-dependent filtration of blood across the
blood-brain barrier (BBB), and the rest originate from drainage
of interstitial fluid from the CNS (2–4). Because CSF is in
direct contact with the CNS, it should be a promising source
for finding biomarkers for diseases in the CNS (5).
Mapping studies characterizing the human CSF proteome
and peptidome has previously been carried out using various
experimental designs, including both healthy and disease-af-
fected individuals (5–16). A total of 2630 proteins were detected
in normal CSF by immunoaffinity depletion of high abundant
proteins followed by strong cation exchange fractionation and
LC-MS (5), whereas proteome and peptidome analyses of hu-
man CSF (collected for diagnostic purposes and turned out
normal) by gel separation and trypsin digestion followed by
LC-MS analysis have shown 798 proteins and 563 peptide
products (derived from 91 precursor proteins) (6). In another
publication, Pan et al. combined several proteomics studies in
CSF from both normal subjects and subjects with neurological
diseases and created a dataset of 2594 identified proteins (16).
But in general, the availability and usefulness of published data
from proteome mapping experiments is scarce, and the format
of the data often makes searching and comparison across
datasets difficult. Thus, organizing the data in online databases
would greatly benefit the scientific community by making the
data more accessible and easier to query. Current online data-
bases containing MS data for CSF include the Sys-BodyFluid,
with a total of 1286 CSF proteins from six studies (17). The
proteome identifications database (PRIDE) (18) includes 19
studies on human CSF, but none reporting more than 103
identified proteins.
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Glycosylation is one of the most common post-translational
modifications (PTMs), and many known clinical biomarkers as
well as therapeutic targets are glycoproteins (19–25). Further-
more, glycosylation plays important roles in cell communica-
tion, signaling, aging, and cell adhesion (26, 27). Nevertheless,
there are few studies on glycoprotein identification in CSF.
One study identified 216 glycoproteins in CSF using both
lectin affinity and hydrazide chemistry (8), and another re-
ported 36 N-linked and 44 O-linked glycosylation sites, from
23 and 22 glycoproteins respectively, by enriching for sialic-
acid containing glycopeptides (28).
Considering the sparse information about the CSF proteome
available in public repositories, we have combined several pro-
teomics approaches to create a map of the global CSF pro-
teome, the CSF glycoproteome, and the respective plasma
proteome from a pool of 21 (20 for the plasma pool) neurolog-
ically healthy individuals. The large amount of data generated
through these four datasets (with linked and complementary
information) would not easily be accessible through existing
repositories. We therefore developed the open access CSF
Proteome Resource (CSF-PR, www.probe.uib.no/csf-pr), an
online database including the detailed data from the four differ-
ent proteomics experiments described in this study. CSF-PR
will be particularly useful in guiding the selection of appropriate
signature peptides for the development of targeted CSF protein
assays.
EXPERIMENTAL PROCEDURES
The workflow of the four different experiments performed in this
study is displayed in Fig. 1A, and described in detail below.
Biological Samples —CSF was collected by lumbar puncture of
neurologically healthy (spinal anesthesia subjects (SAS) (29)) individ-
uals who, under written informed consent, were to undergo spinal
anesthesia for surgery at the Department of Anesthesia and Intensive
Care Medicine, Haukeland University Hospital. Information about the
subjects can be found in supplemental Table S1. Parallel CSF and
plasma samples were collected according to the published consen-
sus protocol for CSF collection and biobanking (30). None of the
patients experienced traumatic CSF taps. CSF samples were centri-
fuged and cells removed prior to proteomics analysis. Plasma was
collected in K2 EDTA tubes and centrifuged at room temperature at
2300  g for 25 min. Aliquots of 500 l CSF from each of the 21
individuals included in this study were combined into a pool. A similar
pool was generated for the plasma samples from 20 of the patients,
as plasma from one patient could not be obtained. The study was
approved by The Regional Committee for Medical and Health Re-
search Ethics of Western Norway.
Chemicals—If not otherwise stated, all chemicals and products
were purchased from Sigma-Aldrich (St. Louis, MO). All protein con-
centrations were measured using a Qubit™ fluorometer kit (Invitro-
gen, Carlsbrad, CA) according to the vendor’s instructions.
Sample Preparation of CSF for SDS-PAGE—3 ml (1400 g protein)
of the CSF pool was up-concentrated to 20 l using 3 kDa ultracen-
trifugation filters (Amicon Ultra-4, Merck Millipore, Billerica, MA), pre-
rinsed with deionized water (MilliQ). The concentrated sample was
protein depleted of 14 high abundant proteins using the human
Multiple Affinity Removal System (MARS HU-14) 4.6 mm x 50 mm LC
column (Agilent Technologies, Santa Clara, CA) according to the
vendor’s recommendations. The two resulting protein fractions (de-
pleted and bound) were then concentrated using ultracentrifugation
filters as described above expect the filters were coated with 1 ml
0.1% N-octyl-Beta-D-glucopyranoside (NOG).
Each fraction was dissolved in LDS sample buffer (Invitrogen)
containing 10 mM DTT (GE Healthcare, Amersham Biosciences,
Buckinghamshire, UK) at 95¦°C for 5 min, alkylated by adding up to 20
mM iodoacetamine (IAA), followed by incubation in room temperature
and in the dark for 20 min, prior to gel separation in two separate
lanes using a lab-casted 20 cm 5–15% SDS-polyacrylamide gradient
gel. Samples were separated at 60 V for 16 h in 1x electrode running
buffer (25 mM Tris base, 192 mM Glysine, and 0.1% SDS diluted in
milliQ water). After protein separation, the gel was stained with Coo-
massie Brilliant Blue (GE Healthcare). The lanes were cut into a total
of 83 gel slices as described in Fig. 1B, 37 slices from the lane with the
bound (high abundant) protein fraction and 46 slices from the lane
with the depleted fraction. The gel slices were in-gel digested (sup-
plemental File S1A) using between 120 and 240 ng of trypsin, de-
pending on the size of the band, before MS/MS analysis.
Sample Preparation of CSF for Mixed Mode Fractionation—1.6 ml
(750 g protein) CSF was concentrated and immunoaffinity depleted
as described above. The entire amount of the depleted fraction (40
g) and an aliquot (100 g) from the bound fraction was in-solution
trypsin digested (Supplementary File 1B), using 0.8 and 2 g trypsin,
respectively. After digestion, the samples were desalted using C18
Oasis™ Elution plates (Waters, Milford, MA) as described elsewhere
(31). The two samples were then fractionated using mixed mode
reversed phase-anion exchange (MM RP-AX) HPLC as described by
Phillips et al. (32). A Promix MP 250 mm x 2.1 mm id, pore size 300
Å column (SIELC Technologies, Prospect Heights, IL) connected to an
Agilent Technology 1260 off-line LC-system was used. The desalted
and dried samples were resuspended in 120 l buffer A (20 mM
Ammonium formate/3% ACN, pH 6.5) and loaded onto the column.
The setup for the LC was as follows. The flow was always 50 l/min
and the gradient length was 70 min. From 0–45 min buffer B (2 mM
Ammonium formate/80% ACN) increased linearly from 15% to 60%,
from 45–55 min 60% B, from 55–65 min 100% B, and from 65–70 min
15% B. The depleted CSF sample was separated into 80 fractions,
where a fraction was collected every 0.87 min from 0–70 min (some
fractions at each end of the gradient were later combined to give the
total number of 66 fractions). Ten fractions were collected for the
bound sample, one fraction the first 2 mins and then one fraction
every 7 mins from 2–70 min.
Sample Preparation of Plasma for Mixed Mode Fractionation—For
the characterization of the plasma proteome, the same experimental
setup as for the CSF characterization using MM (RP-AX) fractionation
was applied to 40 l plasma, representing roughly 2400 g protein.
Preparation of CSF and Isolation of Glycopeptides by Solid-phase
Extraction of N-linked Glycopeptides—Three milliliters (1200 g pro-
tein) CSF was in-solution trypsin digested and further processed by
solid-phase extraction of N-linked glycopeptides (SPEG) essentially
as described in (33) and (34), but with some exceptions. The CSF was
purified and concentrated to 15 l using 3 kDa ultracentrifugation
filters precoated with 1 ml 0.1% NOG. Dilution with 135 l denatur-
ation buffer (8 M Urea/0.4 M Ammonium Bicarbonate (ambic)/0.1%
SDS (Bio-Rad Laboratories, Hercules, CA) followed, and then 120 mM
Tris(2-carboxyethyl)phosphine (TCEP) was added to a final concen-
tration of 10 mM and a one hour incubation at 37¦°C. IAA was added
to a final concentration of 12 mM, and incubated for 30 min in the
dark. The sample was then diluted with 0.1 M ambic until the urea
concentration in the sample was below 1 M, and trypsin digested (1:50
ratio trypsin:protein, Trypsin porcine (Promega, Madison, WI)) over-
night at 37¦°C. The next day the sample was desalted using Oasis
C18, oxidized and desalted again essentially as described in (33), with
some exceptions. 100% formic acid (FA) was used for acidification,
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Oasis plates were used for the desalting, the sample was dried after
the first desalting to remove ACN and resuspended in 400 l 0.1%
TFA before oxidation. The sample was coupled to 4 mg (133 l)
magnetic hydrazide beads (BioClone Inc. San Diego, CA) and further
processed as described in (34). Beads and supernatant were sepa-
rated using a Dynal® magnetic bead separation rack (Invitrogen). The
released and now deglycosylated peptides were collected the follow-
ing day as previously described (33), except that the hydrazide resin
was washed only once and with 200 l ambic, and then acidified with
7 l 5 M hydrochloric acid and 200 l 0.1% FA before desalting by
Oasis C18 as described in (34). The SPEG processing was done in
three separate experiments (1 ml CSF for each), which were com-
bined before further processing.
The digested and SPEG processed sample containing the degly-
cosylated peptides (former glycopeptides) were fractionated into 20
fractions using MM (RP-AX) as described above with the following
set-up: one fraction was collected between 0–2 min, one between
2–7 min, from 7–55 min fractions were collected every 3 min, and from
55–70 min every 5 min. The entire peptide amount from each fraction
was injected for LC-MS analysis.
MS Analysis—Dry samples were dissolved to a final concentration
of 0.1–5% FA before analysis on an LTQ Orbitrap Velos Pro mass
spectrometer (Thermo Fischer Scientific, Bremen, Germany)
equipped with a nano spray Flex ion source (Thermo Fischer Scien-
tific), coupled to a Dionex Ultimate NCS-3000 LC system (Thermo
Fischer Scientific). Approximately 0.5 g of digested protein was
loaded and desalted on a precolumn (Acclaim PepMap 100, 2 cm 
75 m i.d. nanoViper column, packed with 3 m C18 beads) at a flow
rate of 5 l/min for 6 min using an isocratic flow of 0.1% FA (v/v) with
2% ACN (v/v). Peptides were separated during a biphasic ACN gra-
dient from two nanoflow UPLC pumps with flow rate of 280 nl/min on
the analytical column (Acclaim PepMap 100, 15 cm  75 m i.d.
nanoViper column, packed with 2 m C18 beads). Solvent A was
0.1% FA (v/v) with 2% ACN (v/v). Solvent B was 0.1% FA (v/v) with
90% ACN (v/v). The gradient was 0–61.5 min ramp from 8–38% B,
61.5–64.5 min ramp from 38–90% B, and 64.5–69.5 min 90% B,
followed by column conditioning for 12 min with 5% B. Data depend-
ent acquisition was utilized and collision-induced dissociation (CID)
with normalized collision energy of 35% and wideband-activation
enabled. Survey full scan MS spectra (from m/z 300–2000) were
acquired with resolution r  60,000 at m/z 400. The 15 ions with the
highest intensity were selected for MS/MS fragmentation. MS data
were acquired over 90 min.
Analysis of LC-MS/MS Data—The acquired raw files were searched
against the human Swiss-Prot database (from December 2012 -
20,226 entries) using SearchGUI v1.10.4 (35) (search engines:
OMSSA v2.1.9 (36) and X!Tandem CYCLONE (2010.12.01.1) (37)) and
processed in PeptideShaker v0.19.0, http://peptide-shaker.google-
code.com (38). The search criteria were: carbamidomethylation of
cystein as a fixed modification and oxidized methionine as a variable
modification for all datasets. Deamidation of asparagine was set as a
variable modification only for the glyco dataset. Precursor mass tol-
erance was 10 ppm, fragment mass tolerance 0.7 Da, and maximum
number of missed cleavages by trypsin was 2. PeptideShaker con-
verts search engine e-values into confidence values using the distri-
bution of decoy matches as described by Nesvizhskii (39). For all four
of our datasets a validation threshold of 1% false discovery rate was
employed individually at the protein, peptide and peptide spectrum
match (PSM) level. ProteoWizard v.3.0.3650 (40) with default settings
was used to convert the raw files to peak lists. Gene ontology anal-
yses were performed using PANTHER (41).
Analysis of Glyco-data—The resulting data from the mapping of
glycoproteins and -peptides required some manual interpretation to
decide which peptides that were true glycopeptides, and which were
unspecifically bound to the hydrazide beads during the protocol. The
detailed analysis is described in Supplemental File 1C. For a site to be
considered as a true glycosite, the peptide had to have at least one
deamidated asparagine and contain the N-glyco sequence motif
[N][XP̂][ST] (where X can be any amino acid except proline). However,
if the deamidation was confidently assigned only to an asparagine
outside the motif, the peptide was not considered to be a glycopep-
tide. To investigate the chance that a random peptide has both a
deamidated asparagine and the N-glyco sequence motif, we re-
searched the data from the global mixed-mode fractionated and
depleted CSF experiment, but this time with deamidation as variable
modification. After filtering the results, we found that 0.4% of the
peptides in this nonglyco experiment had both a deamidation and the
N-glyco motif, indicating a 0.4% chance for a false positive glyco-
peptide by our approach. Considering that we in addition performed
glycopeptide enrichment in the glyco experiment, this false positive
rate would in reality be even lower. The data postprocessing, per-
formed in PeptideShaker, provides the position of the deamidated
asparagine in the peptide sequence and also a location confidence.
The location confidence tells us how confident the software is in
assigning the modification to the specific amino acid (very confident,
confident, doubtful or random, see Supplemental File 1C for details).
RESULTS AND DISCUSSION
In this study, we performed three LC-MS experiments using
different analytical fractionation strategies to create a library
of proteins and peptides identified in human CSF. For all three
experiments, aliquots of a CSF pool from 21 neurologically
healthy volunteers were used (Fig. 1A). Glycopeptide enrich-
ment in combination with MM (RP-AX) peptide fractionation
was applied in one experiment to map the glycopeptides in
CSF. Immunoaffinity depletion combined with either SDS-
PAGE (Fig. 1B) or MM (RP-AX) fractionation was used for the
two other strategies to map the global CSF proteome. In
addition, immunoaffinity depletion combined with MM (RP-
AX) peptide fractionation was applied to a plasma pool from
20 of the same individuals (Fig. 1A). The number of proteins,
peptides and spectra identified in all the experiments is sum-
marized in Table I.
CSF MM Glyco Mapping—A total of 2594 peptide se-
quences and 598 protein groups were identified in the N-gly-
copeptide enrichment experiment. The maximal protein set
(MPS), which is the sum of all the proteins in all of the protein
groups in the dataset, was 679 whereof 520 were true glyco-
proteins, i.e. having one or more true glycopeptides. The 520
true glycoproteins were represented by 1121 former glyco-
peptide sequences, and 846 specific glycosylation sites (be-
cause of miscleavages some sites were identified in more
than one peptide), and this is to our knowledge the most
comprehensive mapping of glycosylation in CSF.
PeptideShaker and manual inspection of the peptides, as
described in detail in Supplemental File S1C, was used for
assignment of the specific site of deamidation. This assign-
ment is straightforward when the number of deamidations
matches the number of asparagines in the peptide sequence.
Most of the glycopeptides that we identified were in this
category, having only one asparagine in the sequence (665
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peptides). Several other glycopeptides however, had more
than one asparagine in the peptide sequence (459 peptides).
With multiple possibilities for a deamidation, Peptideshaker
uses PTM scores (Ascore (42) and D-score (43)) to assign the
modification to the correct asparagine, and thereby determin-
ing the position of the glyco-unit. When the scoring does not
give certainty about the position of the deamidation (more
than one asparagine in the peptide and not sufficient infor-
mation from the MS/MS spectra), it is doubtfully or randomly
assigned. 202 of our glycopeptides were in this category.
Considering the low probability of a peptide having both a
deamidation and a glycomotif and not being a former glyco-
peptide (calculated to be 0.4% by our approach), and the fact
that we performed glycopeptide enrichment, we find it very
likely that also these peptides are true glycopeptides and that
the position of the deamidation is on the asparagine in the
glycomotif.
Previously, the most comprehensive CSF glycoprotein
study identified 216 glycoproteins in CSF by both lectin affin-
ity and hydrazide chemistry as enrichment strategies prior to
MS analysis (8). After crosschecking our identified glycopep-
tides and glycosylation sites against the Swiss-Prot database
(as described in Supplemental File 1C), we found that 417 of
the identified glycosylation sites were not verified in the da-
tabase. Most of these were as of April 2013 listed as potential
(349 sites), probable (three sites), or by similarity (four sites).
FIG. 1. A, Overview of the workflow of the four different experiments in the study. One experiment included depletion, gel separation,
and trypsin digestion on CSF (left), two experiments included depletion, trypsin digestion, and mixed-mode fractionation on CSF (middle left),
and plasma (middle right), and one experiment included trypsin digestion, glyco-capture by solid-phase extraction of N-linked glycopeptides
(SPEG), and mixed-mode fractionation (right). Orbitrap LC-MS/MS analysis was performed for all four experiments. Glyco-capture figure
adapted from (33) B, Image of the gel after SDS-PAGE separation of the bound (left) and the depleted (middle) protein fraction. The gel MW
standard is shown to the right with the masses marked. Lines across the gel indicate where the bands were excised and point toward the
marked standard masses (right).
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The remaining new sites had no annotation in Swiss-Prot. All
peptides where novel glycosylation sites have been identified
are listed in supplemental Table S2. This is an important
contribution to the field of glycoproteomics.
For some of the proteins several new glycosylation sites
were identified, as for example for neuronal cell adhesion
molecule (nine new sites), protocadherin Fat 2 (nine new
sites), and protocadherin-9 (four new sites). Protocadherins
are known to be involved in brain development (reviewed in
(44)), and knowing the glycosylation characteristics for such
proteins is relevant in order to determine their biochemistry
and function.
CSF SDS-PAGE Global Mapping—The SDS-PAGE frac-
tionation approach (Fig. 1) resulted in the identification of
18,955 peptide sequences and a maximal protein set of 1883
when combining the results from both the depleted and
bound protein fractions f (Table I). As expected, the depleted
fraction accounted for almost all the proteins identified, how-
ever, the analysis of the bound fraction gave an additional 912
peptides and 77 proteins (MPS) of which the majority was
immunoglobulins. The total number of identified proteins
(MPS) from the bound fraction was 441.
Protein Distribution on the SDS-PAGE Gel and Observed
and Theoretical MW—By using the average precursor inten-
sity it was possible to track the intensity distribution of the
peptides (representing corresponding proteins) across the
gel. Fig. 2 shows the number of proteins with peptides iden-
tified in only one fraction (vertical gel slice), two fractions,
three fractions etc., up to all 46 fractions in the depleted gel
lane. As illustrated in the figure, most proteins were identified
in only one, two, or three fractions, and there is a decreasing
trend in the number of proteins (y-axis) as the number of
fractions (x-axis) increases. However, there is a slight increase
toward the end of the x-axis for proteins found in all or almost
all 46 fractions, that is proteins identified across the whole
molecular weight (MW) area of the gel.
The 24 most widespread proteins (present in 45 or 46
fractions, listed in supplemental Table S3) have theoretical
molecular masses ranging from 15.9 kDa (Transthyretin) to
263.5 kDa (Fibronectin). Most of them are present in high
amounts in CSF and high-abundant proteins tend to create
smears in the gel, which could explain why these proteins are
widespread in the gel. Alpha-1-antichymotrypsin, contactin-1,
secretogranin-1, and vitamin D-binding protein (VDBP) are
some of the proteins found in all or almost all fractions of the
gel (Fig. 3A–3D). All these proteins have been suggested as
biomarker candidates for multiple sclerosis and/or other neu-
rological disorders (45–52). Secretogranin-1 is a proprotein
(protein precursor) known to be proteolytically processed in
vivo giving rise to biologically active peptide fragments (53,
54). VDBP is a liver synthesized carrier glycoprotein that
FIG. 2. Number of proteins (y axis)
with peptides observed in from 1 to 46
fractions (x axis) from the immunoaf-
finity depleted and gel separated
sample.
TABLE I
The number of peptides and proteins identified in CSF and plasma
The number of proteins, peptides and spectra identified in the
four CSF datasets and in plasma are indicated. “SPEG” means all
proteins and peptides identified in the glyco enrichment experiment
(including unspecifically bound), while “Glyco” means all proteins
and peptides verified as truly glycosylated by having a deamidation








Mixed-Mode 2779 2632 21,003 170,400
SDS-PAGE 1883 1718 18,955 266,826
SPEG 679 598 2594 14,213
Glyco 520 508 1121 4631
CSF Total 3081 2875 28,811 451,439
Plasma 1050 946 9739 126,164
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FIG. 3. Examples of various average precursor intensity distributions (logarithmic scale) across the 46 fractions from the depleted
and gel separated sample. Fig. shows data for the proteins alpha-1-antichymotrypsin A, contactin-1 B, secretogranin-1 C, vitamin D-binding
protein D, ectonucleotid pyrophosphatase E, neuroserpin F, apolipoprotein D G, and cystatin-C H.
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transports vitamin D (55), and it has over 80 variants listed in
UniProt.
The many fragments and isoforms previously described for
these proteins can also explain their wide distribution in the
gel. Investigating such proteins in a proteomics experiment,
for example, in biomarker discovery and verification studies,
clearly presents challenges. Hence, considerations should be
taken when selecting sample processing methods and pep-
tides to use for targeted quantification experiments in CSF.
During size dependent fractionation, different proteoforms
can be present in different MW areas, and experimental re-
sults could vary depending on what MW area is included in
the sample processing. Thus, our results contribute to guiding
the targeted quantification strategies for proteins observed as
different size variants in CSF.
For other proteins found in multiple fractions the distribution
pattern in the gel varied (Fig. 3E–3H), often with distinct MW
areas with high intensity observations separated by stretches
without any evidence of the protein. This could point toward
the presence of different size isoforms of the protein or indi-
cate that the protein exists both with and without PTMs in-
creasing the MW.
In many cases, we discovered differences between theo-
retical and observed MW of the identified proteins. The pro-
tein neuropilin and tolloid-like protein 2, which is an accessory
subunit of neuronal glutamate receptors, were only found in
the lower mass regions of the gel, although its theoretical
mass is 59 kDa according to UniProt, suggesting the middle
mass region. Also other proteins, such as fibulin-2, TGF be-
ta-1, and multimerin-2 were found at much lower MW areas
than the theoretical, suggesting they have naturally occurring
fragments in CSF. On the contrary, biglycan, serglycin, and
apolipoprotein A-I were observed with MW higher than the
theoretical mass. Biglycan and serglycin are proteoglycans
with glycosaminoglycan chains attached, likely to slow down
the proteins migration in the gel, which could explain this
behavior. Another explanation for this unexpected migration
could be that these proteins form stable complexes not de-
natured in our SDS-PAGE conditions and therefore appear
with higher MW.
Nontryptic Peptides—Information about semi- or nontryptic
peptides, i.e. peptide sequences where trypsin digestion only
appears likely for one of the peptide’s end points, or none of
them, respectively, is also available from this study. The ex-
istence of such nontryptic peptides can indicate that the
protein appears in a truncated form or has peptide fragments
present in CSF. As we identified 57 proteins with protease or
peptidase in their UniProt-assigned protein name, it is likely
that the presence of the nontryptic peptides could be caused
by the activity of these and potentially other proteases present
in CSF. Nontryptic peptides could also be the result of in-
source fragmentation of tryptic peptides (56) and thus not
have a biological explanation. Nevertheless, it is important to
know which peptides that are observed as truncated when
selecting signature peptides for targeted proteomics experi-
ments. The proteins present in many fractions generally have
a higher number of nontryptic peptides associated to them,
indicating the existence of truncation products for these pro-
teins, a possible explanation for the spread observed in the
SDS-PAGE gel.
As an example, for the already mentioned protein secre-
togranin-1, 27 of the 99 validated peptides from our study
were nontryptic. Secretogranin-1 has a theoretical mass of 78
kDa, but is observed in the gel in close to all fractions below
the 148 kDa standard (phosphorylase), as can be observed in
Fig. 3C. A CSF peptidome (and proteome) study performed by
Zougman et al. (6) identified 52 endogenous peptides from
secretogranin-1, the highest number for all the 91 proteins
which they identified. This further suggests that a high number
of molecular weight proteoforms can exist for certain CSF
proteins.
CSF Mixed-mode Global Mapping—As a complement to
the SDS-PAGE approach to identify CSF proteins, we used a
MM (RP-AX) HPLC separation strategy in combination with
immunoaffinity depletion. A total of 21,003 peptide sequences
and 2779 proteins were identified from the depleted and
bound protein fraction. Analysis of the depleted fraction re-
sulted in 18,947 unique peptides and 2661 proteins and the
bound fraction in 845 unique peptides and two unique pro-
teins (Ig alpha-2 chain C region and Ig mu heavy chain dis-
ease protein). The total number of proteins that were ob-
served from the bound fraction in this experiment was 118,
compared with 441 in the SDS-PAGE experiment. Extra cau-
tion should be taken when interpreting the quantitative results
for these proteins in samples depleted using the MARS hu-14
approach.
Three Proteome Mapping Strategies—From our combined
study using three different approaches we found that all sep-
aration strategies provided unique information. The MM (RP-
AX) fractionation strategy clearly resulted in the most identi-
fied proteins (2779 proteins), compared with the gel approach
(1883 proteins), however, in the latter we identified 284 pro-
teins not found in the MM (RP-AX) approach (compared with
1180 unique for MM). In addition, the gel approach provided
important information about the size distribution of the pro-
teins identified.
When comparing the identified glycopeptides with the iden-
tifications from the two global CSF mapping experiments, we
found that 18 proteins were uniquely identified from the glyco
experiment (supplemental Table S4). Most of these were pro-
teins with several potential PTMs, such as glycosylations,
phosphorylations, acetylations, and/or disulfide bonds, which
could make them difficult to identify by the other two ap-
proaches. We also found 148 peptide sequences that over-
lapped between the glyco and global experiments for CSF
(supplemental Table S5). This suggests that these N-glyco
sites are partially occupied, and exist in CSF both as glyco-
sylated and nonglycosylated. Some of the proteins with sev-
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eral partially occupied sites were prostaglandin, major prion
protein, complement factor H, and IgGFc-binding protein.
This information is important when designing targeted quan-
titative assays as two different forms of the peptide/protein
can be quantified. Signature peptides representing both non-
glycosylated asparagine and formerly glycosylated (deami-
dated asparagine after PNGase F treatment) forms should in
these cases be included in the assay.
The Normal Cerebrospinal Fluid Proteome—The most ex-
tensive mapping of proteins in normal CSF published to date
was performed by Schutzer et al. This study provided 2630
identified proteins with IPI identifiers. As our proteins are
identified by UniProt accession numbers, we used the Protein
Identifier Cross-Reference (PICR) conversion tool (57) to con-
vert the IPI identifiers to UniProt accession numbers to be
able to compare the two studies. We were able to confidently
(status: identical) convert 2134 of the 2630 IPI identifications
to UniProt accession numbers. By comparing these to our
maximal protein set of 3081, we found that 1489 proteins
overlapped between the two studies, 645 proteins were
unique for the Schutzer study and 1592 were unique for our
study (supplemental Table S6). Reasons why a relatively high
number of proteins did not overlap between the two studies
could be because of the loss of proteins during the conversion
from IPI identifiers to UniProt accession numbers, differences
in experimental approaches between the two studies, and
differences in instrumentation used.
The patient samples in this study were collected from neu-
rologically healthy patients, who agreed to donate CSF before
undergoing spinal anesthesia for orthopedic surgery typically
in the hips and lower limbs. An alternative to this patient group
would be to investigate CSF from completely healthy volun-
teers, but such samples are hard to obtain because of ethical
aspects as discussed in (29). The proteins present in CSF is
expected to be qualitatively similar between these two
groups, as this is even the case when comparing control
patients to patients with various neurological diseases (31, 47,
58, 59). The concentration of certain proteins would however
expect to vary, but this would mainly influence quantitative
measurements, and not a qualitative study like the one de-
scribed here. So in this regard, the choice of neurologically
healthy patients appears to be appropriate for the purpose of
mapping the CSF proteome, and we anticipate that the pro-
tein content in the database also is highly representable for
other patient groups.
Possible Sample Contaminants—A total of 26 keratin pro-
teins were found in our CSF dataset (nine in the glycodataset)
and four in the plasma dataset. By comparing our identified
proteins against the list of common Repository of Adventitious
Proteins (cRAP, http://www.thegpm.org/cRAP/index.html) pro-
vided by the Global Proteome Machine, representing common
laboratory dust/skin contaminants, we found that at least ten
human keratin proteins and one human salivary protein are likely
to be present in our CSF dataset because of contamination by
skin, hair, or saliva during sample collection or processing. For
the plasma dataset, no proteins matched this list. The remaining
keratins in our dataset are likely to either be naturally present in
CSF and plasma in small amounts, or be the result of contam-
ination during CSF collection or in the further laboratory proc-
essing. When fractionating samples to such an extensive de-
gree as in this study, even small amounts of contaminants could
be identified. The CSF samples included in this study were
chosen based on not showing signs of blood contamination
when visually inspecting the samples or when examined by
SRM against hemoglobin , indicating a very low degree of
blood contamination. Despite this, hemoglobin , , and  were
identified from the pool made from these samples. Likely, this is
because of the extensive fractionation applied in the three ex-
periments, making even marginal protein traces detectable.
Plasma Mixed Mode Mapping—In order to compare the
CSF proteome to the plasma proteome, 40 l of plasma (2400
g protein) from the same individuals were processed and
analyzed in the same way as for the MM (RP-AX) CSF strat-
egy. A total of 9739 peptide sequences and 1050 proteins
(MPS) were identified.
When comparing the proteins identified in CSF with the
proteins identified in plasma, we found that 2204 were only
observed in CSF, 173 were unique for plasma and 877 were
observed in both body fluids. The proteins found uniquely in
plasma were mainly intracellular and involved in metabolic
and cellular processes (gene ontology data not shown), which
could be explained by association to cells or platelets, not
found in CSF. It is likely that the proteins found in both fluids
are mainly plasma derived, because CSF is believed to be, at
least in part, an ultrafiltrate of plasma (reviewed in (60)), and
also because CNS-derived proteins are expected to have a
low abundance in plasma because of dilution. Proteins de-
tected in CSF only could potentially also be present in plasma,
but be below the detection limit of the instrumentation used.
However, most of the proteins uniquely found in CSF are
probably not plasma derived.
To further investigate the origin of the identified CSF pro-
teins, we utilized a recent study from our group (Aasebø et al.
) where the effect of blood contamination in CSF samples was
analyzed (61). Proteins that were affected in concentration by
blood spike-in were considered likely to be blood derived,
whereas proteins unaffected were likely CNS derived. The
over 800 CSF proteins identified in this experiment were com-
pared with our study, and we found that 267 of our total
number of 3081 CSF proteins were affected by blood con-
tamination, 147 were uncertain and 393 were unaffected. This
indicates that most of the proteins identified in our study are
CNS derived, although a large number of proteins could not
be classified as they were not identified in the paper by
Aasebø et al. For the glycodataset specifically, 125 proteins
were affected, 67 uncertain, and 203 were unaffected.
CSF Proteome Resource—One of the goals of this compre-
hensive CSF proteome mapping study was to create a pub-
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licly available database that could be used to easily browse
the CSF proteome as characterized by our extensive LC-MS
analyses. This database, the CSF Proteome Resource (CSF-
PR), is available at http://probe.uib.no/csf-pr, where all the
datasets (glyco, SDS-PAGE, mixed mode, and plasma) are
accessible (Fig. 4). Information retrieved from our database
should be useful for proteomic studies in CSF and the CNS,
and particularly for guiding the selection of suitable signature
peptides for targeted quantification.
CSF-PR serves as a freely available reference library where
information about proteins and peptides identified in CSF can
be retrieved. Protein name, accession number or peptide
FIG. 4. Overview of the CSF Proteome Resource (CSF-PR), showing a selected experiment and the proteins identified in this
experiment, and the distribution of the selected protein across the gel fractions is shown in green bars at the bottom, with gel
standards marked by light blue bars. The slightly darker blue bars represent the range where the protein’s theoretical molecular mass would
suggest that the protein should occur.
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sequence can be searched for in a single experiment, or
across the whole resource. Contained within the resource is
also information about protein inference, MW, confidence (a
transposition of the search engine e-values), sequence cov-
erage, number of peptides and spectra, glycosylation pat-
terns, and whether nontryptic peptides have been identified
for the protein.
The Protein Inference (PI) column, found in both the protein
and peptide Tables in CSF-PR, indicates the degree of protein
inference complexity for the given protein (group) or peptide,
that is, if a peptide is unique for a given protein or shared
between multiple proteins (62). The color scheme goes from
green (single peptide to protein mapping), via yellow (peptide
maps to more than one protein, but these proteins are as-
sumed closely related), to red (peptide maps to more than one
protein, and the proteins are assumed unrelated). Note that
the distinction between related and unrelated proteins should
not be taken as fact, but rather used as an indication for
further inspection of the protein groups.
Information about the distribution of proteins in the SDS-
PAGE gel is also displayed, and peptides identified as formerly
glycosylated are marked with the position of the glycosylation.
The presence of nontryptic peptides is also annotated, pointing
toward truncated versions of the peptide and again the protein.
This might indicate that the peptides are not suitable as surro-
gates for proteins in proteomic analyses.
Furthermore, mapping the corresponding plasma proteome
was important in order to characterize whether the CSF pro-
teins are detected in plasma. The ultimate goal with many
discovery studies using CSF is to verify and validate the
candidate proteins in plasma, a more easily accessible body
fluid with respect to diagnostics and prognostics.
Taken together, CSF-PR is a useful tool for providing an
overview of the CSF proteome, and for guiding the selection
of appropriate signature peptides for proteins to be quantified
in targeted quantification experiments (Fig. 5).
CONCLUSION
We consider the results from our proteomic characteriza-
tion of CSF and the creation of the CSF-PR database as an
important contribution to the field of CSF proteomics re-
search. Especially as an aid in the challenging selection of
signature peptides for targeted protein quantification assays,
and to examine if proteins found in human blood samples
(also provided in the dataset) or proteins from animal brain/
CSF experiments also are present in human CSF, and approx-
imately at what level. Our study contains the highest number
of proteins (3081) and glycopeptides (1121) ever reported for
CSF, including 417 glycosylation sites not previously refer-
enced in Swiss-Prot. The migration and distribution pattern of
CSF proteins in SDS-PAGE is also given, indicating the pres-
ence of many isoforms and PTMs affecting the MW. CSF-PR
differs from other online databases and resources in that it is
optimized for CSF, and significantly extends upon the limited
information known about the critical CSF proteome. This is
important information as this proteome is likely to reflect the
status of the CNS. Accordingly, our objective is to continu-
ously add proteomic experiments to CSF-PR, and to further
develop its functions and use in the future.
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SUPPORTING INFORMATION: The mass spectrometry proteom-
ics data have been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository (63), in seven separate datasets
with the dataset identifiers PXD000651- PXD000657. Part 1
PXD000651 – CSF, gel separated, bound fraction Part 2
PXD000652 – CSF, gel separated, depleted fraction Part 3
PXD000653 – CSF, glyco enriched, mixed-mode separated Part
4 PXD000654 – CSF, mixed-mode separated, depleted fraction
Part 5 PXD000655 – CSF, mixed-mode separated, bound fraction
Part 6 PXD000656 – Plasma, mixed-mode separated, bound frac-
FIG. 5. A proposed workflow for how CSF-PR can be used to
guide the peptide selection for a targeted quantitative experi-
ment, such as SRM. Everything inside the red box can be done in
CSF-PR.
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tion Part 7 PXD000657 – Plasma, mixed-mode separated, depleted
fraction.
All data about proteins and peptides identified in this study, includ-
ing accession numbers, number of distinct peptides for identified
proteins, precursor charges, modifications, score, confidence etc. is
available through CSF-PR at http://probe.uib.no/csf-pr and through
PRIDE. The Supplemental Files (S1A–S1C) contain detailed descrip-
tions for some of the methods. Supplemental File S1A and S1B gives
a description of in-gel and in-solution digestion, respectively, and
Supplemental File S1C gives a detailed description of the analysis of
the glycopeptide data. Supplemental Table S1 includes information
about the 21 subjects who donated the CSF and plasma used in this
study. Supplemental Table S2 lists all the peptides where new gly-
cosylation sites have been identified. Supplemental Table S3 lists the
24 most widespread proteins in the gel in the depleted and gel
separated experiment. Supplemental Table S4 lists the 18 proteins
which were identified only in the glycopeptide enrichment experiment.
Supplemental Table S5 lists the 148 peptides which were identified
both by the global and the glyco approach (true glycopeptides),
indicating partial occupancy of glycosylation sites.
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